Zobrazeno 1 - 10 of 169 pro vyhledávání: '"H Berna Beverloo"'
1
Akademický článek
Targeted treatment options for paediatric B-cell precursor acute lymphoblastic leukaemia patients with constitutional or somatic chromosome 21 alterations
Autor: Naomi Michels, Femke M. Hormann, Aurélie Boeree, Edwin Sonneveld, Anthony V. Moorman, Gabriele Escherich, Rosemary Sutton, H. Berna Beverloo, Rob Pieters, C. Michel Zwaan, Monique L. den Boer, Judith M. Boer
Publikováno v: EJC Paediatric Oncology, Vol 3, Iss , Pp 100140- (2024)
Background: Chromosome 21 is affected in ∼60% of paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients and includes somatic and constitutional gains, intrachromosomal amplification of chromosome 21 (iAMP21), and the transloca
Externí odkaz: https://doaj.org/article/ecb1e835fb504ce692dbd72007e10a05
Zobrazit plný text záznamu
2
Akademický článek
The antioxidant protein peroxiredoxin 4 is epigenetically down regulated in acute promyelocytic leukemia.
Autor: Karishma K Palande, Renee Beekman, Lotte E van der Meeren, H Berna Beverloo, Peter J M Valk, Ivo P Touw
Publikováno v: PLoS ONE, Vol 6, Iss 1, p e16340 (2011)
The antioxidant peroxiredoxin (PRDX) protein family comprises 6 members, which are implicated in a variety of cellular responses, including growth factor signal transduction. PRDX4 resides in the endoplasmic reticulum (ER), where it locally controls
Externí odkaz: https://doaj.org/article/aa86a339bdfb4e6aa17eb5b9f976f862
Zobrazit plný text záznamu
3
Akademický článek
Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial
Autor: Edoardo Pennesi, Erica Brivio, Anneke C. J. Ammerlaan, Yilin Jiang, Vincent H. J. van der Velden, H. Berna Beverloo, Barbara Sleight, Franco Locatelli, Benoit Brethon, Claudia Rossig, Gernot Engstler, Anna Nilsson, Benedicte Bruno, Arnaud Petit, Bella Bielorai, Carmelo Rizzari, Fanny Rialland, Alba Rubio-San-Simón, Francisco J. Bautista Sirvent, Cristina Diaz-de-Heredia, Susana Rives, Christian M. Zwaan
Publikováno v: Haematologica, Vol 999, Iss 1 (2024)
Inotuzumab Ozogamicin (InO) is a CD22-directed antibody conjugated with calicheamicin. The Phase 1B of the ITCC-059 trial tested InO combined with chemotherapy in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Relapsed /refractory
Externí odkaz: https://doaj.org/article/c0f7af8ee2a94f19b2f8e805c1f3d42c
Zobrazit plný text záznamu
4
Akademický článek
Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia
Autor: P. Martijn Kolijn, Alice F. Muggen, Viktor Ljungström, Andreas Agathangelidis, Ingrid L. M. Wolvers-Tettero, H. Berna Beverloo, Karol Pál, Paul J. Hengeveld, Nikos Darzentas, Rudi W. Hendriks, Jacques J. M. van Dongen, Richard Rosenquist, Anton W. Langerak
Publikováno v: Frontiers in Oncology, Vol 11 (2021)
Key processes in the onset and evolution of chronic lymphocytic leukemia (CLL) are thought to include chronic (antigenic) activation of mature B cells through the B cell receptor (BcR), signals from the microenvironment, and acquisition of genetic al
Externí odkaz: https://doaj.org/article/348023aaa5874eb98b52a2826f636eb1
Zobrazit plný text záznamu
5
Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile
Autor: Davine Hofste op Bruinink, Rowan Kuiper, Mark van Duin, Tom Cupedo, Vincent H.J. van der Velden, Remco Hoogenboezem, Bronno van der Holt, H. Berna Beverloo, Erik T. Valent, Michael Vermeulen, Francesca Gay, Annemiek Broijl, Hervé Avet-Loiseau, Nikhil C. Munshi, Pellegrino Musto, Philippe Moreau, Sonja Zweegman, Niels W.C.J. van de Donk, Pieter Sonneveld
Publikováno v: Hofste op Bruinink, D, Kuiper, R, van Duin, M, Cupedo, T, van der Velden, V H J, Hoogenboezem, R, van der Holt, B, Beverloo, H B, Valent, E T, Vermeulen, M, Gay, F, Broijl, A, Avet-Loiseau, H, Munshi, N C, Musto, P, Moreau, P, Zweegman, S, van de Donk, N W C J & Sonneveld, P 2022, ' Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile ', Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol. 40, no. 27, pp. 3132-3150 . https://doi.org/10.1200/JCO.21.01217
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 40(27), 3132-3150. American Society of Clinical Oncology
PURPOSE Primary plasma cell leukemia (pPCL) is an aggressive subtype of multiple myeloma, which is distinguished from newly diagnosed multiple myeloma (NDMM) on the basis of the presence of ≥ 20% circulating tumor cells (CTCs). A molecular marker f
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55ad5570202b354aad1d11a244b64a10
https://doi.org/10.1200/jco.21.01217
Zobrazit plný text záznamu
7
Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial
Autor: Edoardo Pennesi, Naomi Michels, Erica Brivio, Vincent H. J. van der Velden, Yilin Jiang, Adriana Thano, Anneke J. C. Ammerlaan, Judith M. Boer, H. Berna Beverloo, Barbara Sleight, Ying Chen, Britta Vormoor-Bürger, Susana Rives, Bella Bielorai, Claudia Rössig, Arnaud Petit, Carmelo Rizzari, Gernot Engstler, Jan Starý, Francisco J. Bautista Sirvent, Christiane Chen-Santel, Benedicte Bruno, Yves Bertrand, Fanny Rialland, Geneviève Plat, Dirk Reinhardt, Luciana Vinti, Arend Von Stackelberg, Franco Locatelli, Christian M. Zwaan
Publikováno v: Leukemia
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname
Leukemia, 36(6), 1516-1524. Nature Publishing Group
Inotuzumab Ozogamicin is a CD22-directed antibody conjugated to calicheamicin, approved in adults with relapsed or refractory (R/R) B cell acute lymphoblastic leukemia (BCP-ALL). Patients aged 1–18 years, with R/R CD22 + BCP-ALL were treated at the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33daf3144da595f4e65dbc30299e722a
https://doi.org/10.1038/s41375-022-01576-3
Zobrazit plný text záznamu
8
Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Autor: Tim Grob, Adil S. A. Al Hinai, Mathijs A. Sanders, François G. Kavelaars, Melissa Rijken, Patrycja L. Gradowska, Bart J. Biemond, Dimitri A. Breems, Johan Maertens, Marinus van Marwijk Kooy, Thomas Pabst, Okke de Weerdt, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht, Gerwin A. Huls, Jan J. Cornelissen, H. Berna Beverloo, Bob Löwenberg, Mojca Jongen-Lavrencic, Peter J. M. Valk
Publikováno v: Blood, 139(15), 2347-2354. AMER SOC HEMATOLOGY
Blood, 139(15), 2347-2354. American Society of Hematology
Grob, T, Al Hinai, A S A, Sanders, M A, Kavelaars, F G, Rijken, M, Gradowska, P L, Biemond, B J, Breems, D A, Maertens, J, van Marwijk Kooy, M, Pabst, T, de Weerdt, O, Ossenkoppele, G J, van de Loosdrecht, A A, Huls, G A, Cornelissen, J J, Beverloo, H B, Löwenberg, B, Jongen-Lavrencic, M & Valk, P J M 2022, ' Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome ', Blood, vol. 139, no. 15, pp. 2347-2354 . https://doi.org/10.1182/blood.2021014472
Substantial heterogeneity within mutant TP53 acute myeloid leukemia (AML) and myelodysplastic syndrome with excess of blast (MDS-EB) precludes the exact assessment of prognostic impact for individual patients. We performed in-depth clinical and molec
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77bad9fad1fd1beacbd50de3c7c588bf
https://hdl.handle.net/11370/7974a46b-cebd-45b5-8440-d17a4a8c22ab
Zobrazit plný text záznamu
10
Non-Invasive Prenatal Testing Leading to Detection of Asymptomatic Acute Myeloid Leukemia in a 30-Year-Old Patient: A Case Report
Autor: H. Berna Beverloo, Michelle E.M.H. Westerhuis, Mojca Jongen-Lavrencic, Marianne Stenstra, G. Vreugdenhil, Sterre P.E. Willems
Publikováno v: Journal of Hematology
The widely use of non-invasive prenatal testing (NIPT) may lead to accidental findings and the discovery of malignancy in pregnancy, often in asymptomatic patients. Diagnosis of such subclinical malignancy during pregnancy in the asymptomatic patient
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69ebaaba506e2f614517254ca8c403a3
https://doi.org/10.14740/jh908
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje